Presentation to Highlight VK2735's Preliminary
Safety, Tolerability, and Pharmacodynamic
Effects in Healthy Volunteers
SAN
DIEGO, Oct. 10, 2023 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that data from the company's Phase 1 single ascending dose (SAD)
and multiple ascending dose (MAD) clinical trial of VK2735 will be
highlighted as part of an oral presentation at ObesityWeek 2023,
the annual meeting of The Obesity Society. VK2735 is a novel dual
agonist of the glucagon-like peptide 1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) receptors in
development for the potential treatment of various metabolic
disorders such as obesity. ObesityWeek 2023 is being held
October 14-17, 2023, at the Kay
Bailey Hutchison Convention Center in Dallas, Texas.
The oral presentation will provide an overview of previously
reported results from Viking's Phase 1 SAD/MAD study of VK2735 in
healthy volunteers with a BMI ≥30. In addition, new findings
related to the impact of VK2735 on subjects' liver fat content and
plasma lipid levels will be reported.
Details of the oral presentation are as follows:
Oral Presentation #089:
- Title: First-in-Human Single and Multiple Dose
Study of the Dual GLP-1/GIP Agonist VK2735 in Healthy
Adults
- Presenting Author: Joel
Neutel, M.D., Orange County Research Center
- Date/Time: Tuesday, October
17, 2023, at 11:45 a.m. Central
Time
- Location: D174
About GLP-1 and Dual GLP-1/GIP Agonists
Activation of the glucagon-like peptide 1 (GLP-1) receptor has
been shown to decrease glucose, reduce appetite, lower body weight,
and improve insulin sensitivity in patients with type 2 diabetes,
obesity, or both. Semaglutide is a GLP-1 receptor agonist that has
been approved by the U.S. Food and Drug Administration and is
currently marketed in various dosage strengths and forms as
Ozempic®, Rybelsus®, and Wegovy®.
More recently, research efforts have explored the potential
co-activation of the glucose-dependent insulinotropic peptide (GIP)
receptor as a means of enhancing the therapeutic benefits of GLP-1
receptor activation. Tirzepatide is a dual GLP-1/GIP receptor
agonist that is currently in clinical development for obesity.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. The company's clinical
programs include VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders, which is currently being
evaluated in a Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for
the treatment of non-alcoholic fatty liver disease (NAFLD) and
elevated LDL-C, patients who received VK2809 demonstrated
statistically significant reductions in LDL-C and liver fat content
compared with patients who received placebo. The company is also
developing VK2735, a novel dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors for the potential treatment of various metabolic
disorders. Data from a Phase 1 trial evaluating VK2735 (dosed
subcutaneously) for metabolic disorders demonstrated an encouraging
safety and tolerability profile as well as positive signs of
clinical benefit. The company also recently initiated a Phase 1
study to evaluate an oral formulation of VK2735. In the rare
disease space, the company is developing VK0214, a novel, orally
available, small molecule selective thyroid hormone receptor beta
agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1b clinical trial in patients with
the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds
exclusive worldwide rights to a portfolio of five therapeutic
programs, including VK2809 and VK0214, which are based on small
molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding Viking Therapeutics, Inc., under the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, including statements about Viking's expectations regarding
its clinical and preclinical development programs and cash
resources. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially and adversely and reported results should not be
considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: risks
associated with the success, cost and timing of Viking's product
candidate development activities and clinical trials, including
those for VK2735, VK0214, VK2809, and the company's other incretin
receptor agonists; risks that prior clinical and preclinical
results may not be replicated; risks regarding regulatory
requirements; and other risks that are described in Viking's most
recent periodic reports filed with the Securities and Exchange
Commission, including Viking's Annual Report on Form 10-K for the
year ended December 31, 2022, and subsequent Quarterly Reports
on Form 10-Q, including the risk factors set forth in those
filings. These forward-looking statements speak only as of
the date hereof. Viking disclaims any obligation to update
these forward-looking statements except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-highlight-data-from-phase-1-clinical-trial-of-dual-glp-1gip-receptor-agonist-vk2735-in-oral-presentation-at-obesityweek-2023-301952436.html
SOURCE Viking Therapeutics, Inc